Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

NCT02014844 ↗

Phase 2 Completed 28 enrolled ImmunityBio, Inc.

RandomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.

Timeline

Start: 2014-03
Primary completion: 2016-12
Completion: 2016-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aldoxorubicin	Small molecule	250 mg/m2	Intravenous
Subject	Aldoxorubicin	Small molecule	350 mg/m2	Intravenous

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

Summary

Timeline

Drugs

Indications